XI’AN, China, Nov. 12 /Xinhua-PRNewswire-FirstCall/ -- Skystar Bio-Pharmaceutical Co., Ltd. (“Skystar” or the “Company”) today announced that it will conduct a conference call at 10:30 a.m. Eastern Time on Friday, November 16, 2007 to discuss the third quarter 2007 financial results.
Joining Mr. Weibing Lu, Chairman and Chief Executive Officer of Skystar, will be Ms. Erna Gao, Chief Financial Officer, Mr. Scott Cramer, Director and U.S. representative, and Mr. Wei Wen, Secretary and Director. The Company plans to make its earnings announcement prior to the call.
To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: 866- 800-8648. International callers should dial 617-614-2702. When prompted by the operator, mention Conference Passcode 629 683 64.
If you are unable to participate in the call at this time, a replay will be available for seven days starting on Friday, November 16, 2007 at 12:30 p.m. Eastern Time. To access the replay, dial 888-286-8010 and enter the passcode 899 525 43. International callers should dial 617-801-6888 and enter the same passcode.
In addition, the conference will be broadcast live over the Internet and can be accessed by all interested parties at the Company’s corporate website at http://www.skystarbio-pharmaceutical.com/ . To listen to the call please go to the website at least 15 minutes prior to the start of the call to register, download and install any necessary audio software.
About Skystar Bio-Pharmaceutical
Skystar Bio-Pharmaceutical Company is a China-based producer and distributor of vaccines, microorganisms and veterinary medication to cure and prevent disease in poultry, livestock, birds and pets. The company’s product line consists of more than 100 products with over 50 additional products in the developmental stage. Skystar has formed strategic sales distribution networks throughout China. The company recently completed the first phase of construction of new state-of-the-art bio-pharmaceutical facilities covering an area of almost eight acres. The new facilities meet or exceed all Good Manufacturing Practice (GMP) Certification Standards and have received GMP Certification from the Chinese government. For additional information, please visit http://www.skystarbio-pharmaceutical.com .
scramer@skystarbio-pharmaceutical.comcrocker.coulson@ccgir.comleslie.richardson@ccgir.com
CONTACT: Scott Cramer, Director -- U.S. Representative for Skystar
Bio-Pharmaceutical Co., Ltd., +1-407-645-4433, or
scramer@skystarbio-pharmaceutical.com; Crocker Coulson, President of CCG
Elite Investor Relations, crocker.coulson@ccgir.com; Leslie Richardson,
Financial Writer for CCG Elite Investor Relations, +1-310-231-8600 x 122,
or leslie.richardson@ccgir.com, all for Skystar Bio-Pharmaceutical Co.,
Ltd.
Web site: http://www.skystarbio-pharmaceutical.com/
